Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Principal Scientist at Intellia Therapeutics
Amy Rhoden Smith is a Principal Scientist at Intellia Therapeutics leading a platform group focused on RNA for CRISPR/Cas9 applications, ranging from development and optimization of Cas9 mRNA to synthetic guide RNA. Prior to her joining Intellia in June 2015, Amy was at Moderna Therapeutics where she developed chemical and biochemical hybrid approaches to modify mRNA. Amy’s research has focused on using chemistry to understand and solve biological problems, and she continues to do so in her role at Intellia. She received her B.S. in Chemistry from College of Charleston, and completed her Ph.D. in Organic Chemistry at the University of Texas at Austin.